are you gilead. >> i am gilead. >> bottom line. >> >> they still have to buy some.t's the gym add story. >> that i have to create something. that's where they are lacking. i think amgen to guy's point on this sell-off, you look at the pipeline, they lowered the low end of the guidance going forward. there is a lot of reasons that this does create an opportunity. this sell-off i think is the opportunity to buy a little am begin. i like your ibb idea, but i like this individual name on the sell-off. >> let's move on, shares of buffalo wild wings falling, susan lee is at the headquarters to break it all down. >> they are engaged right now, a nasty proxy battle with activist monsanto capital. buffalo wild wings under pressure to try to improve the business t. quarter pretty much added into ul to the case as earnings missed, revenue was inline. ceos were up a meeker half of a percent. it beat low street expectations. half priced wing tuesday apparently helped sales, higher cost, hurt buffalo's bottom line. >> best trends are the challenge of rising labor costs and we uni

gilead has had a brutal run. once a $140 billion market cap. down to $87 billion.at balance sheet. >> acquisition. until they do something, they've got to do something. you know what? i can give you a list of a half dozen companies they have to buy. >> right. will they? they did try on medivation, hanging around and cellgene, but pfizer bought it. interesting to note not the level of acquisition activity some might have expected from buyers such as gilead or even a cellgene. or an amgen. >> pfizer and merck their stocks have been stuck here. >> we're not going to show any of those. we have to show the nasdaq. >> j&j said they needed to do it. the consumer business was weak. that's interesting. that's cvs, everyone is excited because of the pharmacy benefit. get the deal express scripps wants. you're freaking out about the nasdaq 6,000? >> i'm not. i'm not but the control room apparently is. >> control room? >> take a minute to talk about what this means here, jim. it surpasses the five handle levels of the dot-com boom. the thousand point thresholds to get from fiv

gilead sciences ad: be sure to ask your doctor to get tested for hep c. when do you think is behind that in terms of this affiliation you describe with the pharmaceutical industry and academics? annie waldman: when the hepatitis c cure came out, it was incredibly expensive, and the reason was because the, the first pharmaceutical company that released the cure wanted to set the price at the highest point that the market would bear. so, they started pushing and they pushed congressmen, they pushed academics, they pushed doctors in order to get everybody tested so that they would have to purchase the cure; however, our government can't afford to spend all this money to save everyone, so they started rationing the drugs. sharyl: what's wrong with the pharmaceutical industry trying to convince the government that these are good products and what's wrong with them getting paid whatever the market will allow them to make for all that research and development that they've done? annie waldman: well, we all want innovation. we all want cures. and in other countrie

looking at pfizer, merck, gilead and cellgene, on the target side, companies as big as alexion and insided tesaro. we seen tesaro stock down as they put out plans to launch their new cancer drug. people take that to mean maybe they won't be a potential target. biotech earnings check in week. they are saying it could be a mixed bag in terms of performance, of folks who could beat, looking at potentially alexion, cellgene where they think amgen comes in. on the positive side. you haven't seen negative pre announcements, for these companies, meaning it could go well. there is seasonal weakness. on the positive sidesh that means from an investment standpoint, drug price increases are still happening, even amid this, 40 in this year versus 23 in 2016. they seem like they're accelerating right now. >> maybe they're smaller? maybe they're smaller. however, there was a really interesting no doubt from credit suisse showed it came from drug price increases. >> all were drug price increase? >> their growth 8.7 billion in growth. 100% drug increases. >> staggering. >> meg mentioned tsr. >> tesora. >

. >> we talk gilead all the time. >> that will be the savior if they make that move. >> bio tech had nice performance. it's turned its fortunes around and been strong as a lot of other trade have gone weak. have you been hearing from analysts that the tourists if space are coming back, there is a return to favor for biotech? >> it's certainly not a strong return to favor for biotech. the street.com had an interesting article talking about the biotech. there is not a lot of volume, not a lot of interest. we are not seeing blockbuster may deals as they continue political pressure. people kind of waiting for big exciting data for a big deal, something for everybody to get jazzed about this space again. >> the resilience is surprising. it gets back to a place, it's not every one of these companies, maybe there is megahigh growth at reasonable valuation, to me, it's a proxy playoff, if anything, i would be betting against it. >> betting against it, interesting. >> mech, thank you. >> major stock therapy. i have a long weekend. you can't have "options action"s, though. >> thank you. >> unl

world, america's democracy and constitution have fallen, replaced by a theocratic autocracy called "gilead." >> ladies, i have to let you go. >> brown: a place where women have lost the right to work or own property. where many of them are property. >> you girls will serve the leaders and their barren wives. you will bear children for them. >> brown: the so-called "handmaids" are valued, and controlled, for their ability to reproduce, in a future america where most women are infertile. designated by their bonnets and red dresses, they are kept under an ever-watchful eye. >> i made sure that every horrific detail in the book, had happened sometime, at somewhere. so, think of it as a cake in which, i made the cake, but all of the raisins and chocolate chips are real. >> brown: the series "the handmaid's tale" is based on the classic 1985 novel of the same name, by canadian author margaret atwood. she calls it "speculative fiction." >> i get in trouble over making a distinction between sci-fi and speculative fiction, but my only point is that there is a difference between a galaxy far, far aw

it showed you that health care besides gilead and -- >> facebook was number six on the owned list. >>ounder still owns a good chuchk of that. >> that's true. intel for people making their choices. see everybody tomorrow. fast money begins now. >>> "fast money" starts right now. live from the nasdaq mark site, i'm melissa lee. tonight on fast, the nasdaq hitting a record again today for the 21st time this year. the mysterious north man trader said there's something in the charts spelling trouble ahead. he'll be here to explain. plus, we've got five stocks that are skyrocketing. we'll tell you the underthe radar winners and whether the high flyers have more room to run. president trump gets ready to meet with the president of china. could this be the big market-movingnt